論文

国際誌
2021年9月28日

Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals.

Life (Basel, Switzerland)
  • Kazuya Kishimoto
  • ,
  • Yuji Nozaki
  • ,
  • Toshiharu Sakurai
  • ,
  • Koji Kinoshita
  • ,
  • Masanori Funauchi
  • ,
  • Itaru Matsumura

11
10
記述言語
英語
掲載種別
DOI
10.3390/life11101019

We report a 14-year-old man with Crohn's disease (CD) who developed right upper arm pain while being treated with the anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, infliximab. There were no symptoms suggestive of active CD, but the inflammatory response was high, and a contrast-enhanced CT showed the occlusion of the right brachial artery. We diagnosed the patient as having Takayasu's arteritis (TA) and started treatment with corticosteroids, then tapered off the steroids as the symptoms of TA resolved. Later, TA flared up, and his treatment was changed from infliximab to an anti-IL-6 receptor antibody, tocilizumab. The change to TCZ stabilized TA, but exacerbated CD. It is difficult to control both diseases at the same time, and the choice of biologics for treatment must be carefully considered.

リンク情報
DOI
https://doi.org/10.3390/life11101019
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34685390
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537758
ID情報
  • DOI : 10.3390/life11101019
  • PubMed ID : 34685390
  • PubMed Central 記事ID : PMC8537758

エクスポート
BibTeX RIS